Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

JNJ 107.86 +0.38 (0.35%)
price chart
Johnson & Johnson's Go-To Business Schools
Everybody has his or her favorites, and top MBA employers are no different. Many of the most coveted employers focus on a relatively small handful of MBA programs, hiring far more graduates at those schools than anywhere else.
Johnson & Johnson Names New Chairman
William C. Weldon, the chairman of Johnson & Johnson, is stepping down at the end of this year and will be succeeded by Alex Gorsky, the current chief executive, the company announced Friday.
Johnson & Johnson Elects CEO Gorsky Chairman  Fox Business
Johnson & Johnson Chief Gorsky Elected to Chairman  Bloomberg
Related articles »  
Dr. Buffett Has Diagnosed Johnson & Johnson As Too Big To Succeed
In conclusion, Berkshire's history with Johnson & Johnson is a good reminder to investors of the need to cut their losses on an investment.
Johnson & Johnson, Merck and Eli Lilly to rip red tape from clinical trials
Johnson & Johnson's ($JNJ) Janssen R&D unit is leading a charge to expedite the tedious process of selecting sites for clinical trial sites, with the creation of a investigator database intended to get studies up and running more efficiently.
J&J, Lilly, Merck plan clinical trial site database  Reuters
J&J, Lilly and Merck join forces on clinical trials  PMLiVE
Related articles »  
J&J says it won't enforce AIDS drug patent in Africa
LONDON (Reuters) - Generic manufacturers are to be given a free rein to make cheap copies of Johnson & Johnson's HIV/AIDS drug Prezista for sale in Africa and other poor countries.
J&J Won't Enforce Patents on HIV Medicine in Africa  Businessweek
Related articles »  
Johnson & Johnson One-Ups Tuberculosis
In an 18-0 ruling on efficacy, the FDA advisory committee voted in favor of Johnson & Johnson's bedaquiline, a drug to combat multidrug-resistant tuberculosis.
FDA panel says novel TB drug is safe  Vaccine News Daily (blog)
Related articles »  
Amgen, Johnson & Johnson, Bernstein Litowitz, and the fraud on the market theory
You might remember that the Center for Class Action Fairness objected to a $0 settlement in Johnson & Johnson. The objector argued that the settlement provided no benefit to shareholders.
J&J's Global Media Review Hits Halfway Mark
Johnson & Johnson is midway through a global review of its media planning and buying business with its decision in the North American market this week.
Insurance And Income: Protecting Johnson & Johnson
The next choices were two different married put combinations on Johnson & Johnson with a January 2014 expiration. The deeper in-the-money put, the 2014 January 75 strike put option offers a maximum risk of only 5.5%, whereas the 2014 January 72.5 ...
Johnson & Johnson Campaign for Nursings Future turns 10
Ten years ago a nursing shortage loomed in the United States. A shortfall of about 400,000 nurses by 2020 was projected and, between 1983 and 1998, the proportion of RNs younger than 30 had dropped from 30% to 12%, according to a 2000 article in the ...
Related articles »